Bioniche closes funding, licensing deal with Paladin
08 July, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has gained access to a further C$5m in funding after closing its debt refinancing and Urocidin licensing deal with Paladin Labs.
Novogen gets up to $5m to fund CS-6 development
08 July, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has signed a deal with a US investor that will give it access to up to $5m in working capital to help take cancer drug candidate CS-6 into the clinic.
Pharmaxis, Phylogica and LBT win ARC grants
05 July, 2013 by Dylan Bushell-EmblingPharmaxis (ASX:PXS), Phylogica (ASX:PYC) and LBT Innovation (ASX:LBT) will all receive Australian Research Council linkage grants for projects with universities.
pSivida initiates posterior uveitis trial
04 July, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) has commenced recruitment for one of two planned US phase III trials of its injectable micro-insert in posterior uveitis.
CSL progresses therapies for haemophilia
04 July, 2013A new group of therapies is showing promise for the treatment of haemophilia.
Review of employee share schemes announced
04 July, 2013AusBiotech was pleased to learn that the government has announced it will review the policy settings around employee share schemes (ESS).
Phylogica advances collaboration with Janssen
02 July, 2013 by Dylan Bushell-EmblingPhylogica (ASX:PYC) has identified peptide candidates in its drug-discovery collaboration with Janssen Biotech and will move on to exploring their functionality within cells.
AusBiotech wins grant to engage in Asia
02 July, 2013AusBiotech was among the 27 member-based business organisations that have been awarded grants to help them expand their networks in Asia. The grants were provided under the Australian Government’s inaugural Asian Century Business Engagement plan and announced by the Hon Kelvin Thomson, Parliamentary Secretary for Trade, last Friday.
Phosphagenics investigation
02 July, 2013An independent financial investigation is underway at Phosphagenics.
Carr returns to industry portfolio
02 July, 2013Kevin Rudd’s new cabinet, sworn in yesterday, will see Kim Carr return to take up the industry and innovation and higher education portfolio.
REVA Medical recruiting in A/NZ for stent trial
01 July, 2013 by Dylan Bushell-EmblingREVA Medical (ASX:RVA) has commenced recruitment for the Australia/New Zealand arm of its CE Mark trial for ReZolve 2, a bioresorbable cardiac scaffold.
Phylogica enhances peptide screening capabilities
28 June, 2013 by Dylan Bushell-EmblingPhylogica (ASX:PYC) has improved its Phylomer peptide screening platform to allow it to discover candidates that can penetrate cell walls and deliver drug cargoes to a specific target.
Global Medisafe makes it to market
27 June, 2013 by Dylan Bushell-EmblingGlobal Medisafe Holdings has launched its first Clik-Lok safety syringe product in Europe and will soon start the process of securing Australian approval.
R&D Tax Bill introduced to parliament
27 June, 2013A Bill was yesterday introduced into parliament to jointly legislate for quarterly credits for companies entitled to the refundable 45% R&D Tax Incentive and to enact the $20 billion turnover cap for companies to be eligible for the 40% non-refundable R&D tax offset, as announced as part of the government’s A Plan for Australian Jobs in February.
Biotech’s industry conference returns to Qld: early bird about to close
25 June, 2013With early-bird registrations about to close (28 June), preparations have kicked into top gear at AusBiotech as the team prepares to return the industry event of the year to Brisbane, Queensland, from 30 October-1 November 2013.
